High frequency of antibodies to Hantaan virus and hepatitis C virus in chronic haemodialysis patients. Coincidence or cross-reaction?

Loading...
Thumbnail Image

Date

Authors

Tsianos, E. V.
Dalekos, G. N.
Elisaf, M. S.
Zervou, E.
Siamopoulos, K. C.

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Type of the conference item

Journal type

peer-reviewed

Educational material type

Conference Name

Journal name

J Intern Med

Book name

Book series

Book edition

Alternative title / Subtitle

Description

OBJECTIVES: To address the question of whether there is any coincidence or cross-reaction between hepatitis C virus (HCV) and Hantaan virus (both RNA arboviruses), as well as to assess the frequency of antibodies to the above viruses amongst chronic haemodialysis patients in our region. DESIGN: Collection of serum samples from consecutive unselected chronic haemodialysis patients. SETTING: A tertiary referral center (University Hospital). SUBJECTS: One hundred and fourteen chronic haemodialysis patients were investigated for the presence of antibodies to HCV (anti-HCV) and Hantaan virus disease (anti-HVD). Eleven unselected non-haemodialysis patients with well-defined haemorrhagic fever with renal syndrome (HFRS) were also investigated for the anti-HCV antibodies comprising the disease control group. INTERVENTIONS: None. MAIN OUTCOME MEASURES: The utility of an anti-HVD positive test in chronic haemodialysis patients. RESULTS: Seventeen patients (14.9% 95% confidence interval [CI] 8.4-21.4%) were anti-HCV positive, whereas 15 (13.2%, 95% CI 6.9-19.3%) were anti-HVD positive. An anti-HCV positive test was confirmed by recombinant immunoblot assay (RIBA II) in 88.2%. The presence of anti-HCV antibodies was not associated with transfusions but with the longer duration of haemodialysis (62.8 +/- 29.8 vs. 31.2 +/- 29.3 months, P < 0.001). Anti-HVD antibodies were not associated with transfusions or with the duration of haemodialysis. Three patients were positive for both anti-HCV and anti-HVD antibodies. None of the 11 patients with well-defined HFRS had anti-HCV antibodies. CONCLUSIONS: Chronic haemodialysis patients are a high risk group for HCV infection in association with the duration of haemodialysis and, at least for our geographical area, these patients have to be examined for anti-HVD antibodies especially when a definite causative agent for chronic renal failure is not found. The HVD and HCV infection are not exceptional amongst haemodialysis patients in our region, whereas the possibility of a cross-reaction between these two RNA arboviruses is rather excluded as there was no evidence of HCV infection amongst the patients with well-defined HFRS.

Description

Keywords

Adolescent, Adult, Aged, Antibodies, Viral/*blood, Cross Reactions, Female, Hantaan virus/*immunology, Hepacivirus/*immunology, Hepatitis Antibodies/blood, Humans, Male, Middle Aged, *Renal Dialysis

Subject classification

Citation

Link

http://www.ncbi.nlm.nih.gov/pubmed/8258753
http://onlinelibrary.wiley.com/store/10.1111/j.1365-2796.1993.tb01021.x/asset/j.1365-2796.1993.tb01021.x.pdf?v=1&t=h0ma4dcr&s=4cbbb6a47b9503838c419a691b501c7519c9cf3d

Language

en

Publishing department/division

Advisor name

Examining committee

General Description / Additional Comments

Institution and School/Department of submitter

Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής

Table of contents

Sponsor

Bibliographic citation

Name(s) of contributor(s)

Number of Pages

Course details

Endorsement

Review

Supplemented By

Referenced By